Global New Oral Anticoagulants Market 2025 To 2034

New Oral Anticoagulants Market Size, Trends and Insights By Drug Type (Dabigatran (Pradaxa), Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban (Savaysa/Lixiana), Betrixaban (Bevyxxa)), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation (AF), Stroke Prevention, Others (e.g., orthopedic surgery prophylaxis)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034. Reports Description As per the New Oral Anticoagulants Market conducted by the CMI Team, the global New Oral Anticoagulants Market is expected to record a CAGR of 7.24% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 42.5 Billion. By 2034, the valuation is anticipated to reach USD 79.6 Billion. For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=72428新型口服抗凝药（New Oral Anticoagulants）市场规模、趋势及行业洞察，按药物类型（达比加群（Dabigatran，Pradaxa）、利伐沙班（Rivaroxaban，Xarelto）、阿哌沙班（Apixaban，Eliquis）、依度沙班（Edoxaban，Savaysa/Lixiana）、贝曲沙班（Betrixaban，Bevyxxa））、应用场景（深静脉血栓形成（Deep Vein Thrombosis，DVT）、肺栓塞（Pulmonary Embolism，PE）、心房颤动（Atrial Fibrillation，AF）、卒中预防、其他（如骨科手术预防））、分销渠道（医院药房、零售药房、线上药房）及区域进行划分——涵盖全球行业概览、统计数据、竞争分析、市场份额、行业前景及2025-2034年市场预测。 报告说明 据CMI团队开展的新型口服抗凝药市场研究显示，2025至2034年，全球新型口服抗凝药市场的复合年增长率（Compound Annual Growth Rate，CAGR）预计将达7.24%。2025年，该市场规模预计将达到425亿美元；到2034年，市场估值有望达到796亿美元。 如需了解更多信息，请立即访问https://www.custommarketinsights.com/request-for-free-sample/?reportid=72428 下载免费样本报告